thyroid neoplasms/tyrosine

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 33 rezilta yo

Cancer and Blood Pressure Management, CARISMA Study

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVE: I. To determine the feasibility of an intensive (systolic blood pressure [SBP] < 120 mmHg) "Intervention" versus standard care (SBP < 140 mmHg) "Non-Intervention" approach to blood pressure (BP) control in metastatic renal cell and thyroid cancer patients initiating

Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Even though the prognosis of advanced GIST has been tremendously improved by the introduction of tyrosine kinase inhibitors, the vast majority of patients will develop secondary resistance to these agents. The therapeutic options of patients with advanced GIST with resistance (or intolerance) to

Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study is design to prospectively investigate the safety and efficacy of apatinib in downsizing primary tumors and metastatic lesions in patients with metastatic and advanced differentiated thyroid cancers before RAI Treatment. Standard treatment of thyroid cancer includes thyroidectomy, RAI

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Soft tissue sarcoma (STS) is a relatively rare type of malignant tumor. For patients with recurrent/distant metastasis/unresectable advanced soft tissue sarcoma, chemotherapy with doxorubicin and ifosfamide is the standard treatment, but the effect is limited. Targeted drugs represented by

Rehabilitation Program in Patients With Acromegaly

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Acromegaly is a rare, chronic, disabling disease of endocrine origin that causes several debilitating systemic dysfunctions due to the excessive production of growth hormone (GH) and insulin-like growth factor I (IGF-I) (Gadelha et al., 2017). In 98% of cases, the disease is caused by a sporadic

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Population: Patients with advanced progressive 131I-refractory DTC or MTC will be enrolled to this study. Forty-five patients responding to TKI therapy (defined as 50% drop in tumor marker level within the first two months of treatment) will be randomized to receive TKI therapy either through

Cabozantinib in Advanced Salivary Gland Cancer Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Rationale: Salivary gland cancer (SGC) is a rare cancer with 24 histological subtypes. Treatment options for locally advanced and/or metastatic SGC are limited. The tyrosine kinase inhibitor cabozantinib suppresses tumor growth, angiogenesis, and metastasis, and has been approved for renal cell

Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.The study is a randomised,multicentre,double-blind,placebo-controlled,study.

Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

See brief summary

Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Bladder cancer is the 9th most common cancer worldwide, with around 429.800 new cases diagnosed in 2012 and the 5th most common cancer in Europe, with more than 151.000 new cases diagnosed in 2012. Relating mortality figures, bladder cancer is the 13th most common cause of cancer death worldwide,

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This is a Phase I/II research study, which means that researchers are testing different doses of the drug alectinib in participants with cancer to evaluate its safety, determine a safe dosage range, and identify side effects. The FDA (the U.S. Food and Drug Administration) has approved alectinib as

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Primary Outcome Measure: Progression free survival of apatinib in RAIR-DTC. Secondary Outcome Measures: Disease control rate, objective response rate, duration of response, changes of Tg and TgAb level in serum, overall survival, side effects and quality of life.

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This phase 2 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess efficacy and safety in patients with 131I-refractory/resistant differentiated thyroid cancer.The study is a randomised,multicentre,open-label study.

Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Carcinomas of the salivary glands (SGCs) are rare, (less than 1% of all cancers of the head and neck and include more than 20 malignant histotypes. They can occur both in major and minor salivary glands, are locally aggressive, demonstrating invasiveness that leads to involvement of the facial

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye